Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
Columbia University · with Stevens Institute of Technology, Stanford University · NCT06839469
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 5+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 106
- US sites recruiting
- 3
- Study start
- May 1, 2024
- Record last updated
- April 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.
Conditions: Spinal Muscular Atrophy Type 3; Duchenne Muscular Dystrophy (DMD)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Genetic confirmation of disease (DMD, SMA) or healthy control
- Able to walk independently at least 25 meters
- Ongoing corticosteroids therapy or initiation of corticosteroid therapy in the previous 3 months for DMD
- Stable dose of FDA approved SMN up-regulator therapy or in an open-label extension phase of a study treatment for at least 6 months for SMA or gene replacement at enrollment for SMA or DMD participants.
Exclusion Criteria
- Use foot orthoses or assistive devices for community ambulation or a mobility device for community navigation
- Use investigational medications intended for treatment of NMD within 30 days
- Prior to study entry had an injury or surgery that would impact gait within the previous 3 months
Recruiting US locations
Stanford University
Palo Alto, CA 94304
Site contact: Sally Dunaway Young, PT, DPT · 650-497-0075 · sdy@stanford.edu
Boston Children's Hospital
Boston, MA 02115
Site contact: Amy Pasternak, PT, DPT · 617-355-7212 · amy.pasternak@childrens.harvard.edu
Columbia University Irving Medical Center
New York, NY 10032
Site contact: Jacqueline Montes · 212-305-8916 · jm598@cumc.columbia.edu
Study contacts (from the official record)
- Jacqueline Montes, PT, EdD · 212-305-8916 · jm598@cumc.columbia.edu
- Cara Kanner, DPT · 516-581-8150 · chy2112@cumc.columbia.edu
Similar studies in California
All healthy volunteers studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- Rialto, CA + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Lake Forest, CA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55